Results 21 to 30 of about 61,872 (307)

Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy

Frontiers in Neurology, 2023
Amyloidoses represent a group of diseases characterized by the pathological accumulation in the extracellular area of insoluble misfolded protein material called “amyloid”.
L. Poli, Beatrice Labella, S. Cotti Piccinelli, F. Caria, B. Risi, Simona Damioli, Alessandro Padovani, M. Filosto   +7 more
semanticscholar   +1 more source

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Global Heart, 2023
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and fatal condition that requires early diagnosis, management, and specific treatment.
Dulce Brito, Fabiano Castro Albrecht, Diego Perez de Arenaza, Nicole Bart, Nathan Better, I. Carvajal-Juárez, I. Conceição, Thibaud Damy, S. Dorbala, Jean-Christophe Fidalgo, P. García-Pavía, Junbo Ge, J. Gillmore, Jacek Grzybowski, L. Obici, Daniel Piñero, Claudio Rapezzi, Mitsuharu Ueda, Fausto J. Pinto   +18 more
semanticscholar   +1 more source

RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis

BioDrugs, 2023
Transthyretin (TTR) is a tetrameric protein synthesized primarily by the liver. TTR can misfold into pathogenic ATTR amyloid fibrils that deposit in the nerves and heart, causing a progressive and debilitating polyneuropathy (PN) and life-threatening ...
A. Ioannou, M. Fontana, J. Gillmore
semanticscholar   +1 more source

Placental transfer of a hydroxylated polychlorinated biphenyl and effects on fetal and maternal thyroid hormone homeostasis in the rat [PDF]

, 2002
Earlier studies at our laboratory indicated that several hydroxylated polychlorinated biphenyls (OH-PCBs) detected in human blood could specifically inhibit thyroxine (T4) transport by competitive binding to the thyroid hormone transport protein ...
Assink, Y., Berg, J.H.J. van den, Bergman, A., Brouwer, A., Cenijn, P.H., Koeman, J.H., Meerts, I.A.T.M., Weijers, B.M.   +7 more
core   +7 more sources

Restrictive Atrial Dysfunction in Cardiac Amyloidosis: Differences between Immunoglobulin Light Chain and Transthyretin Cardiac Amyloidosis Patients

Biomedicines, 2022
Background: In cardiac amyloidosis, the prevalence of thromboembolic events and atrial fibrillation is higher in transthyretin amyloidosis compared to immunoglobulin light chain amyloidosis.
Mathijs O. Versteylen, Maaike Brons, Arco J. Teske, Marish I. F. J. Oerlemans   +3 more
doaj   +1 more source

A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)

Orphanet Journal of Rare Diseases, 2023
Background Transthyretin amyloidosis (ATTR amyloidosis) is a progressive, multisystemic, life-threatening disease resulting from the deposition of variant or wild-type (ATTRwt amyloidosis) transthyretin amyloid fibrils in various tissues and organs ...
L. Gentile, Teresa Coelho, A. Dispenzieri, I. Conceição, M. Waddington-Cruz, A. Kristen, J. Wixner, Igor Diemberger, J. González-Moreno, E. Cariou, M. Maurer, V. Planté-Bordeneuve, P. García-Pavía, I. Tournev, J. González-Costello, Alejandra Gonzalez Duarte, M. Grogan, Anna Mazzeo, Doug Chapman, Pritam Gupta, Oliver Glass, L. Amass   +21 more
semanticscholar   +1 more source

Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy

JAMA cardiology, 2023
Key Points Question Does tafamidis, 80 mg, affect cardiac function in patients with transthyretin amyloid cardiomyopathy? Findings In this post hoc analysis of the randomized Tafamidis in Transthyretin Cardiomyopathy Clinical Trial including 441 patients,
Sanjiv J. Shah, Nowell Fine, P. García-Pavía, Allan L Klein, Fábio Fernandes, Neil J. Weissman, M. Maurer, Kurt Boman, B. Gundapaneni, M. Sultan, Perry M. Elliott   +10 more
semanticscholar   +1 more source

Uncovering the Mechanism of Aggregation of Human Transthyretin. [PDF]

, 2015
The tetrameric thyroxine transport protein transthyretin (TTR) forms amyloid fibrils upon dissociation and monomer unfolding. The aggregation of transthyretin has been reported as the cause of the life-threatening transthyretin amyloidosis.
Cascio, Duilio, Eisenberg, David S, Jiang, Lin, Johnson, Lisa M, Liang, Wilson Y, Riek, Roland, Ruchala, Piotr, Saelices, Lorena, Sawaya, Michael R, Whitelegge, Julian   +9 more
core   +2 more sources

Improved long‐term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms

European Journal of Heart Failure, 2023
The value of disease‐modifying therapies (such as tafamidis) in patients with transthyretin amyloid cardiomyopathy (ATTR‐CM) and severe heart failure symptoms has been debated.
P. Elliott, B. Gundapaneni, M. Sultan, M. Inês, P. García-Pavía   +4 more
semanticscholar   +1 more source

Decreased transthyretin predicts a poor prognosis in primary myelodysplastic syndrome

Frontiers in Nutrition, 2023
BackgroundThis study aims to investigate the prognostic significance of transthyretin in newly diagnosed myelodysplastic syndromes (MDS).MethodsThe clinical, laboratory, and follow-up data of 280 newly diagnosed patients with MDS were collected.
Ying Chen, Ying Chen, Tingting Niu, Tingting Niu, Ting Chen, Ting Chen, Yue Wu, Yue Wu, Duobing Zou, Duobing Zou, Cong Shi, Cong Shi, Ying Wu, Ying Wu, Zhaoyi Zhang, Zhaoyi Zhang, Ningning Wu, Ningning Wu, Yi Zhang, Yi Zhang, Xiao Yan, Xiao Yan, Lixia Sheng, Lixia Sheng, Dingfeng Lv, Guifang Ouyang, Guifang Ouyang, Xueqin Chen, Qitian Mu, Qitian Mu   +29 more
doaj   +1 more source